A multi-center, randomized, double-blind,placebo-controlled study comparing 80 mg of adalimumab with placebo, and demonstrating the non-inferiority of monthly 80 mg adalimumab dosing compared with 40 mg adalimumab every other week dosing.
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 10 Jun 2017 Biomarkers information updated
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 03 Jul 2013 Last checked against European Clinical Trials Database record.